About Fenwalinc
Fenwalinc is a Healthcare company based in Lake Zurich (United States) founded in 1949, and was acquired by Fresenius Kabi in July 2012. Portfolio of products for transfusion medicine and cell therapy. Its Indian entity Fenwal India Private Limited reported revenue of βΉ10.6 Lakh. The company was acqui-hired. Its focus areas include Life Sciences, Hematology, Medical Devices and Therapeutic. Its competitors include Medcura, ExThera Medical and CytoPherx; 3 of its 3 listed competitors have raised funding.
Company details
Fenwal(acquired by Fresenius Kabi in 2012) is a blood technology company producing products to support transfusion medicine and cell therapy. Its offerings include medical technologies used in blood separation, collection, filtration, storage and transfusion. Some of its products are component collection systems, separators, and plasmapheresis systems, manual collection products, segment sampling devices, tubing sealers, sterile tube connection systems, hemoglobin screening devices, donor chairs, donor tube strippers, transfer packs, transfusion sets, platelet and cellular sample transfer kits, bone marrow kits. Fenwal Inc. was owned by Baxter Healthcare Corporation till 2007 when it was sold by Baxter to Texas Pacific Group (TPG) and Maverick Capital. In 2012, it was acquired by Fresenius Kabi
- Headquarters Lake Zurich, United States
- Stage Acquired
- SectorsHealthcare
- Website fenwalinc.com
- Social LinkedIn X
- Acquired by Fresenius Kabi (Jul 2012)
- Legal Name Fenwal India Private Limited
- Date of Incorporation 18 Jan, 2007
- Jurisdiction Gurgaon, Haryana, India
- Indian entity revenue₹10.6 Lakh
FY 2019 · +1% YoY
- Indian entity net loss-₹38.5 Lakh
FY 2019 · -363% margin
- Indian entity EBITDA-₹38.5 Lakh
FY 2019 · -363% margin
- Investors
- Acquired byFresenius Kabi
(Jul 2012)
Associated legal entities of Fenwalinc
Fenwalinc operates through Fenwal India Private Limited (dissolved under section 59(8)). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2019) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Fenwal India Private Limited CIN U24305HR2007PTC040846 | Dissolved Under Section 59(8) | 18 Jan 2007 | Gurgaon, Haryana | ₹0.1 Cr | 2 | View details |
Investors in Fenwalinc
Fenwalinc has secured backing from 1 investor. Prominent investors backing the company include Fresenius Kabi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare solutions in pharmaceuticals, nutrition, MedTech, and biopharmaceuticals. | 1999 | fresenius-kabi.com |
Investor details for Fenwalinc
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Fenwal India Private Limited (Fenwalinc)
Fenwal India Private Limited is the primary company behind Fenwalinc. The board of Fenwal India Private Limited currently have 2 directors; the longest-serving is Govind Ram Cheyyur, appointed in 2014. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Govind Ram Cheyyur DIN 06948443 | Director | 05 Sep 2014 | 12 yrs 2 mo | Fenwal India Private Limited |
| Ashish Mukund Kulkarni DIN 06998433 | Director | 20 Oct 2014 | 12 yrs 1 mo | Fenwal India Private Limited |
Financials of Fenwalinc
Figures of Fenwal India Private Limited, the primary company behind Fenwalinc, for FY 2019. Revenue was ₹10.6 Lakh (+1% year on year). Net loss was -₹38.5 Lakh (-363% margin). EBITDA was -₹38.5 Lakh (-363% margin). Revenue has grown at a compounded annual rate of -82% over three years.
- ₹10.6 LakhRevenue · FY 2019 · +1% YoY
- -₹38.5 LakhNet loss · -363% margin
- -₹38.5 LakhEBITDA · -363% margin
- ₹31.40 CrPaid-up capital
- -82%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Fenwal India Private Limited are on its company page.
Detailed financial statements for Fenwalinc
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Fenwalinc
2 dated milestones of Fenwalinc across 63 years, from founding to its latest funding, stage changes and deals.
- Founded Fenwalinc is founded.
- Exit Acquired by Fresenius Kabi.
Competitors of Fenwalinc
Fenwalinc has 3 listed competitors in our database, 3 of them funded. They include Medcura, ExThera Medical and CytoPherx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medcurainc.com | 2019 | United States | $87.35M | Developer of the device for controlling bleeding | ||
| extheramedical.com | 2007 | Berkeley, United States | $54.59M | 23 | Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking | |
| cytopherx.com | 1994 | Ann Arbor, United States | $45.69M | Cytopheresis systems for inflammatory conditions |
Detailed competitors of Fenwalinc
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fenwalinc
Websites that share an audience with Fenwalinc (fenwalinc.com).
Websites whose visitors overlap most with Fenwalinc. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hemocue.us | hemocue.us | 100% | β | ||
| haemonetics.com | 98% | 50.5K | #632,767 | View details | |
| terumobct.com | 95% | 56.6K | #599,470 | View details | |
bonfils.org | bonfils.org | 94% | #14,898,013 | β | |
| giveapint.org | 94% | #1,113,140 | View details | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 9 similar websites and full traffic analytics for Fenwalinc
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Hematology
3 companies that operate in the same segment as Fenwalinc (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fenwalinc
Complete news archive for Fenwalinc
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fenwalinc
Fenwalinc was founded in 1949.
Fenwalinc is headquartered in Lake Zurich, United States. It is registered at Lake Zurich, Illinois, United States.
The primary company behind Fenwalinc, Fenwal India Private Limited, reported revenue of βΉ10.6 Lakh for FY 2019, up 1% year on year.
Fenwal(acquired by Fresenius Kabi in 2012) is a blood technology company producing products to support transfusion medicine and cell therapy. Its offerings include medical technologies used in blood separation, collection, filtration, storage and transfusion. Some of its products are component collection systems, separators, and plasmapheresis systems, manual collection products, segment sampling devices, tubing sealers, sterile tube connection systems, hemoglobin screening devices, donor chairs, donor tube strippers, transfer packs, transfusion sets, platelet and cellular sample transfer kits, bone marrow kits. Fenwal Inc. was owned by Baxter Healthcare Corporation till 2007 when it was sold by Baxter to Texas Pacific Group (TPG) and Maverick Capital. In 2012, it was acquired by Fresenius Kabi.
Fenwalinc's top competitors include Medcura, ExThera Medical and CytoPherx.
Fenwalinc has 1 investor. Key investors include Fresenius Kabi.
Fenwalinc operates through Fenwal India Private Limited.
Yes. Fenwalinc was acquired by Fresenius Kabi in July 2012.
The legal entities of Fenwalinc currently have 2 directors, including Govind Ram Cheyyur, Ashish Mukund Kulkarni.

